Hodgkin's disease and Epstein-Barr virus;Maladie de Hodgkin et virus d'Epstein-Barr: Physiopathoiogie et perspectives thérapeutiques

Annales de Biologie Clinique

Volumn 62, Issue 6, 2004, Pages 639-648

  Depil, S ^a,b   Morales O ^b   Auriault, C ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

EBV; Hodgkin's disease; Immunotherapy

Indexed keywords

EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; VIROLOGY; VIRUS INFECTION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; PROGNOSIS;

HUMAN HERPESVIRUS 4;

EID: 9644260644     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000 ; 343 : 481-92.
2. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004 ; 350 : 1328-37.
3. Kurth J, Hansmann ML, Rajewsky K, Kuppers R. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA 2003 ; 100 : 4730-5.
4. Kuppers R. B cells under influence : transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003 ; 3 : 801-12.
5. Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998 ; 187 : 1395-402.
6. Hoshino Y, Morishima T, Kimura H, Nishikawa K, Tsurumi T, Kuzushima K. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection. J Immunol 1999 ; 163 : 5735-40.
7. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002 ; 195 : 893-905.
8. Schmidt CW, Misko IS. The ecology and pathology of Epstein-Barr virus. Immunol Cell Biol 1995 ; 73 : 489-504.
9. White CA, Cross SM, Kurilla MG, et al. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus- specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 1996 ; 219 : 489-92.
10. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 2001 ; 75 : 8649-59.
11. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995 ; 59 : 387-405.
12. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000 ; 54 : 19-48.
13. Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A. The importance of exogenous antigen in priming the human CD8+ T cell response : lessons from the EBV nuclear antigen EBNA1. J Immunol 2000 ; 165 : 7078-87.
14. Tellam J, Connolly G, Green KJ, et al. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004 ; 199 : 1421-31.
15. Lee SP, Brooks JM, Al-Jarrah H, et al. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med 2004 ; 199 : 1409-20.
16. Voo KS, Fu T, Wang HY, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004 ; 199 : 459-70.
17. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2001 ; 75 : 3740-52.
18. Wilson AD, Redchenko I, Williams NA, Morgan AJ. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol 1998 ; 10 : 1149-57.
19. Khanolkar A, Yagita H, Cannon MJ. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. Virology 2001 ; 287 : 79-88.
20. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 2002 ; 99 : 3302-9.
21. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989 ; 320 : 502-6.
22. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991 ; 337 : 320-2.
23. Jaffett RF. Viruses and Hodgkin's lymphoma. Ann Oncol 2002 ; 13 (Suppl. 1) : 23-9.
24. Nalesnik MA, Randhawa P, Demetris AJ, Casavilla A, Fung JJ, Locker J. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993 ; 72 : 2568-73.
25. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999 ; 17 : 3122-7.
26. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003 ; 349 : 1324-32.
27. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989 ; 320 : 689-95.
28. Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 2004 ; 125 : 267-81.
29. Enblad G, Sandvej K, Lennette E, et al. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Int J Cancer 1997 ; 72 : 394-7.
30. Axdorph U, Porwit-MacDonald A, Sjoberg J, et al. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 1999 ; 81 : 1182-7.
31. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer 2001 ; 84 : 1227-34.
32. Flavell KJ, Billingham LJ, Biddulph JP, et al. The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol 2003 ; 14 : 282-90.
33. Clarke CA, Glaser SL, Dorfman RF, et al. Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer 2001 ; 91 : 1579-87.
34. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR. Hodgkin's disease in the elderly : a population-based study. Br J Haematol 2002 ; 119 : 432-40.
35. Enblad G, Sandvej K, Sundstrom C, Pallesen G, Glimelius B. Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncol 1999 ; 38 : 425-9.
36. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999 ; 84 : 442-8.
37. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000 ; 111 : 239-46.
38. Wagner HJ, Schlager F, Claviez A, Bucsky P. Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Eur J Cancer 2001 ; 37 : 1853-7.
39. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease : Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994 ; 91 : 10962-6.
40. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996 ; 184 : 1495-505.
41. Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997 ; 94 : 9337-42.
42. Watanabe K, Yamashita Y, Nakayama A, et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000 ; 36 : 353-61.
43. Re D, Muschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001 ; 61 : 2080-4.
44. Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993 ; 82 : 2937-42.
45. Masy E, Adriaenssens E, Auriault C, Coll J. La protéine oncogène LMP1 du virus d'Epstein-Barr : voies de signalisation et phénotypes associés. Virologie 2002 ; 6 : 379-90.
46. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 1996 ; 15 : 3117-26.
47. Gaines JD, Gilmer MA, Remington JS. Deficiency of lymphocyte antigen recognition in Hodgkin's disease. Natl Cancer Inst Monogr 1973 ; 36 : 117-21.
48. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002 ; 99 : 4283-97.
49. Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002 ; 198 : 310-6.
50. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004 ; 103 : 1755-62.
51. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001 ; 61 : 6219-26.
52. Flanagan J, Middeldorp J, Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J Gen Virol 2003 ; 84 : 1871-9.
53. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998 ; 91 : 2925-34.
54. Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002 ; 84 : 175-201.
55. Heslop H, Rooney C, Brenner M, et al. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther 2000 ; 11 : 1465-75.
56. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004 ; 100 : 1892-901.
57. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen : a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001 ; 93 : 706-13.
58. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003 ; 101 : 1905-12.
59. Duraiswamy J, Bharadwaj M, Tellam J, et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 2004 ; 64 : 1483-9.